Investigational drug · Phase 3
BNT113
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BNT113"
First trial start
2021
Jan 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BNT113", any sponsor or status.
Conditions studied
As listed on its trial records.
- Unresectable Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Cancer
- Recurrent Head and Neck Cancer
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BNT113" as an intervention, largest first.
- A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1Pivotal-lookingActive, not recruiting
BioNTech SEIndustry
NCT04534205 · 358 participants · Start Jan 7, 2021 · Primary completion Apr 2029
Drug: BNT113; Pembrolizumab · For: Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer
Sites: Los Angeles, California; Palo Alto, California; New Haven, Connecticut · 136 sites in all
- HARE-40: HPV Anti-CD40 RNA vaccinECompleted
University of SouthamptonAcademic, hospital or other
NCT03418480 · 30 participants · Start Apr 11, 2017 · Primary completion Nov 1, 2023
Drug: BNT113 · For: Human Papilloma Virus Related Carcinoma; Head and Neck Neoplasm; Cervical Neoplasm and 2 more
Sites: Southampton, United Kingdom; Manchester, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Shared-Antigen Cancer Vaccines Keep Falling Short.
· Cancer Discov 2026
- mRNA vaccines targeting HPV E6/E7: A new frontier in cervical cancer immunotherapy.
Aftabsavad S, Arashkia A, Shokrgozar MA, et al. · Crit Rev Oncol Hematol 2026
- Translational Challenges and Opportunities in mRNA Cancer Vaccines.
Jeong SD, Schrank BR, Mancuso JJ, et al. · Cancer Discov 2026
- Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation.
Filippini DM, Le Tourneau C · Transl Oncol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.